As the $1,000 genome has been realized, human society is rapidly advancing into the era of precision medicine that is capable of predicting, diagnosing, and treating diseases based on big data that integrates medical and genomic information. Recognizing the importance of genomic medicine as a key to innovative change in the medical paradigm and the realization of precision medicine, we have made outstanding progress in research in the field of genomic analysis. Particularly, we became the fourth company in the world to analyze the entire genome of Koreans with the individual genome analysis results in 2009 and the first when it comes to Northern Asian genome analysis results. In 2016, we managed to overcome the limitations of the existing international standard genome and achieve the world's most complete Asian standard genome applicable to future precision medicine.

Macrogen has constantly evolved and adapted to the changing market for the last two decades and is prepared to become the global No. 1 company in the "Genome Foundry" industry by expanding its domestic and international genome centers' operations based on the new management structure and the mid-to-long term vision called "Macrogen 2.0." Macrogen is currently striving to take another leap in the clinic business by providing health check-up services tailored to each person's genes for disease predictions at its medical institutions, including Macrogen Medical Foundation's Gene Health Check-up Center. While vertically integrating our business areas including the upstream and downstream businesses related to DNA analysis, Macrogen, a healthcare company with a pivot on "wellness," will continue to expand our global network. Furthermore, Macrogen will continue making progress toward the goal of empowering humans to achieve longevity without diseases by tapping into the digital transformation in healthcare empowered by the convergence of big data, including genomic data, and AI-driven analysis technologies.